Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Zepbound is the tirzepatide product indicated for long-term weight reduction in adults with obesity or with overweight plus at least one weight-related comorbid condition, and for moderate to severe obstructive sleep apnea in adults with obesity
The FDA approved Rybelsus in 2019 and oral Wegovy in 2025 (Rybelsus was rebranded as oral Ozempic in 2026)
The jump from $399 to $499 at the 10mg dose is significant because many users need higher doses to achieve their weight loss goals
Retatrutide Retatrutide Triple agonist (GLP-1 / GIP / GCG) under investigation in metabolic research
Losing weight too quickly can lead to health problems, and the weight may come back just as quickly as it was lost
US$ 23.78
US$ 20.46
US$ 27.38
US$ 20.90
US$ 21.64
US$ 28.22
